ALS Clinical Trials in Phoenix

Showing 21-35 of 35 trials

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

NCT02794857

This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation. Half of participants will receive NP001 and the other half will receive placebo.

Amyotrophic Lateral Sclerosis

Neuraltus Pharmaceuticals, Inc.138 participantsStarted Aug 2016

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Los Angeles, California, United States +19 more locations

UNKNOWNPHASE1/PHASE2< 1 mile

Determining the Safety of L-serine in ALS

NCT01835782

The purpose of this study is to determine the safety of L-Serine in subjects with Amyotrophic Lateral Sclerosis (ALS) at varied doses.

Amyotrophic Lateral Sclerosis (ALS)

Phoenix Neurological Associates, LTD20 participantsStarted Jan 2013

Phoenix, Arizona, United States • San Francisco, California, United States

PreviousPage 2 of 2

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

Determining the Safety of L-serine in ALS

ALS Trials in Other Cities

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

Creatine for the Treatment of Amyotrophic Lateral Sclerosis

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS

Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation

Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

Other Conditions in Phoenix